AstraZeneca To Shut Indian API Site

AstraZeneca is shuttering its Indian active pharmaceutical ingredient unit in Yelahanka, Bangalore in a move the UK-based firm says was triggered by low export demand for the key product made there.

AstraZeneca PLC has already shut its Indian R&D site and has now decided to close an active pharmaceutical ingredient (API) unit in the country, following an application to the Drugs Controller General of India to retract its local manufacturing license for terbutaline sulfate (TBS), a beta 2 agonist used in asthma.

"TBS was manufactured predominantly for export and the company applied to withdraw the manufacturing licence due to low demand for...